Health Condition 1: D80-D89- Certain disorders involving the immune mechanism
Conditions
Interventions
Intervention1: DEC drug: After the initial assessment, the patients will be diagnosed and categorized into one of the four groups as Mild intermittent Allergic Rhinitis, Mild persistent Allergic Rhini
Sponsors
Prem Davis
Eligibility
Inclusion criteria
Inclusion criteria: 1. Age: >18 years 2. Symptoms of Allergic Rhinitis â?? two or more symptoms of anterior or posterior rhinorrhea, Sneezing, nasal blockage, itching, watering of eyes, nasal and pharyngeal itching during two or more consecutive days for more than one hour on most days. 3. Patients not on any antiallergic medications and DEC for the past 2 weeks.
Exclusion criteria
Exclusion criteria: Exclusion Criteria 1. Pregnant Women 2. K/C/O Diabetes Mellitus with Random Blood Sugar values of >200mg/dl with oral and injectable antidiabetic drugs. 3. Allergic Fungal Rhinosinusitis 4. Past History of Nasal Surgery 5. Immunocompromised Patients (Patient with History of frequent infection, immunosuppressant therapy, history of chemo or radiotherapy) 6. Tumors of nose and paranasal Sinuses. 7. Hypersensitivity to Diethylcarbamazine
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pre-treatment Assessment and Post-treatment Assessment was compared with Total Nasal Symptom Score, Absolute eosinophils count, nasal smear for eosinophil, Diagnostic Nasal Endoscopy and Mini Rhinoconjuctivitis Quality of Life QuestionnaireTimepoint: Assessment will be made at baseline and after 21 days of treatment. | — |
Secondary
| Measure | Time frame |
|---|---|
| NilTimepoint: Nil | — |
Countries
India
Contacts
Public ContactPrem Davis
Sri Venkateshwaraa Medical College Hospital and Research Centre, Ariyur, Puducherry
Outcome results
None listed